On May 12, 2022 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that the company management team, along with guest key opinion leaders (KOLs), will provide an update for the investment community on Thursday, June 2nd at 4:30 PM (Press release, Aptose Biosciences, MAY 12, 2022, View Source [SID1234614316]). The event will include an up-to-date review of clinical data available for Aptose’s two investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The slides will be available on Aptose’s website here and a recording of the presentation will be archived shortly after the conclusion of the event.

Separately, preclinical data for HM43239 also will be presented in a poster at the EHA (Free EHA Whitepaper)2022 Hybrid Congress, to be held in Vienna, Austria June 9 – 17, 2022 and virtually. The accepted abstract is being published today, Thursday, May 12th at 16:00 CEST / 10:00 AM ET.